Social•Mar 1, 2026
NMN Restores NAD, Shields Heart via SIRT3
According to ITOA, NAD declines with age, causing epigenetic changes & disease susceptibility In 2010, we showed NAD-dependent enzyme, SIRT3, protects the heart 🐁 New study says NAD precursor NMN protects the heart via SIRT3 in mice fed a Western diet https://www.sciencedirect.com/science/article/pii/S0022316626000842
By David Sinclair
Social•Mar 1, 2026
OpenADMET Releases Massive CYP Assay Datasets for Community AI
OK. Here it is. Over the last year, the @OctantBio and OpenADMET team have been hard at work developing scalable, quantitative, data-rich, and low-cost methods for assessing CYP reactivity and inhibition. The interplay between building a data engine and building...
By Sri Kosuri
Social•Feb 28, 2026
Welireg Poised to Broaden Reach per GU26 Data
$MRK Welireg could be about to expand its reach at last. #GU26 data via @ApexOnco with relevance to $RCUS -> https://t.co/k59284INdK
By Jacob Plieth
Social•Feb 28, 2026
Miami Preps for Biotech Week; BiotechTV Covers Barclays Conference
Looks like Miami is getting ready for biotech week (the week after next). Note: BiotechTV will be broadcasting from the Barclays conference March 10 & 11. https://t.co/ToZH0EgOVz
By Brad Loncar
Social•Feb 28, 2026
IL11 Deficiency Causes Female Infertility, Low Weight, Osteoporosis
But note IL11 knockout mice are infertile (females) and have low body weight and some osteoporosis. Still interesting angle though.
By Peter Suzman
Social•Feb 28, 2026
Paper on Target Trial Emulation Overlooks Confounding by Indication
How is it that a paper that claims to show how to do target trial emulation does not address confounding by indication and its ramifications for data collection? https://t.co/dzGZZdpBoc #Statistics
By Frank Harrell
Social•Feb 28, 2026
Accelerating CAR Engineering Shows Promising Cancer Immunotherapy
Some very good news about engineering our cells vs cancer (accelerating the CAR). A short thread 1. For background, a new 5★ review on cancer immunotherapy @Cancer_Cell https://t.co/1Qz2rCs8I5 https://t.co/sJ6BwaXyjk
By Eric Topol
Social•Feb 28, 2026
Single-Cell Atlas Links Marrow Immune Dysregulation to Myeloma Outcomes
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma https://t.co/5t0M2eX0fB https://t.co/p3kv8LEzrC
By Ming Tang
Social•Feb 27, 2026
Generate Biomed IPO Marks AI‑Driven Protein Breakthrough
This morning @generate_biomed celebrated its IPO on the @NasdaqExchange. We founded Generate at @FlagshipPioneer in 2018, asking: What if we could generate novel protein therapeutics using generative AI tools – without relying on traditional trial-and-error discovery? Today’s IPO is a major...
By Noubar Afeyan
Social•Feb 27, 2026
Comparing Lorigerlimab, Volrustomig, Cadonilimab: Design Lessons
An intriguing tale of three cities. How do the PD1xCTLA4 bispecific agents lorigerlimab, volrustomig, and cadonilimab stack up when it comes to design and performance? Some useful and pointed lessons here for biotech execs: https://t.co/xaSW15Fvdl https://t.co/dhXbiI3N6v
By Sally Church
Social•Feb 27, 2026
Atrium Launches to Tackle Rare Heart Diseases with RNA
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA https://t.co/xLp2oQDHGy $RNA $NVS #startups
By Ben Fidler
Social•Feb 27, 2026
De Novo Proteins Expected in Clinics Within Two Years
“The era of de novo proteins is coming a lot faster than probably people recognize,” Generate's CEO Mike Nally tells me. “I think within the next year or two you’ll start seeing de novo designs enter the clinic.” https://t.co/u3WQcDD3jL
By Andrew Dunn
Social•Feb 27, 2026
AI Automation Threatens Life Sciences Lab Jobs
The Block layoff news was a big deal yesterday. I’m sorry to say that ML driven automated labs are going to do the same to lab jobs in life sciences that AI is starting to do to other industries.
By Brad Loncar
Social•Feb 27, 2026
Smartphone AI Beats Endocrinologists in Acromegaly Diagnosis
AI is helping to make the diagnosis of rare diseases. A new multicenter study in Japan showed smartphone AI diagnosis of acromegaly via hands was better than experienced endocrinologists https://t.co/qBiazetToV https://t.co/dSZpJ2us84
By Eric Topol
Social•Feb 27, 2026
Novo's Missteps Echo Bristol Myers' Strategic Failure
Elizabeth Cairns' piece on $Novo is reminiscent of Bristol Myers' strategic fail against Merck and Keytruda. They were focused on the wrong things, made bad trial design decisions and got stuck in the mud of their own making. Everyone should...
By John Carroll